Express Scripts is suing the Federal Trade Commission (FTC) over a July 2024 report it claims is misleading and harmful to the pharmacy benefit manager (PBM) industry.

The Federal Trade Commission staff is having trouble getting information from the big pharmacy benefit managers, but it believes that the big PBMs may have too "outsized influence" over the U.S ...

What they found: The PBMs marked up prices for specialty generic drugs by hundreds and sometimes thousands of percent over their estimated acquisition costs from 2017 and 2022, per the FTC report.

There's little point in pouring hundreds of millions of dollars into creating a biosimilar if PBMs will refuse to cover it.

The FTC released a 60-page report Tuesday targeting the biggest three pharmacy benefit managers, claiming the companies hiked the prices of specialty drugs to generate $7.3 billion in revenue from ...

The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying the major industry middlemen generate billions in revenue through ...

Another FTC Commissioner, Andrew Ferguson, said, although he concurs with the release of the report on PBMs, he added it was important to mention the “unusual nature of this particular interim ...

The interim staff report, which is part of an ongoing inquiry launched in 2022 by the FTC, details how increasing vertical integration and concentration has enabled the six largest PBMs to manage ...

The FTC should produce a full report that provides empirical analysis of PBMs and the healthcare market. Policymakers at every level depend on it to sort through the noise of politics to make ...

The FTC’s First Interim Report found that pharmacies affiliated with the three largest PBMs in the United States received 68 percent of all revenue for dispensing specialty drugs in 2023 (up ...

The FTC report was the product of a PBM investigation that the FTC announced in 2022. Investigators ended up looking at both PBMs and prescription drug group purchasing organizations.

The FTC report has a “clear ideological bias” and makes misleading claims about PBMs that could lead to policies that would inflate drug costs, Cigna Chief Legal Officer Andrea Nelson said in ...